The effect of protein kinase C inhibition on renal and peripheral hemodynamic function in patients with type 1 diabetes mellitus

Trial Profile

The effect of protein kinase C inhibition on renal and peripheral hemodynamic function in patients with type 1 diabetes mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Ruboxistaurin (Primary)
  • Indications Diabetic nephropathies
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 17 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top